For the treatment of infections caused by susceptible microorganisms in the complicated skin and skin structure infections and complicated intra-abdominal infections for patients 18 years of age or older.

Tigecycline, a bacteriostatic glycylcycline, is a derivative of minocycline. It inhibits protein synthesis in susceptible bacteria by reversibly binding to 30S ribosomal subunit, thereby blocking entry of amino-acyl Trna molecules into the A site of the ribosome. Tigecycline has a broad spectrum of antibacterial activity. Tigecycline ’s role in therapy is an alternative treatment for severely ill patients, especially with resistant infections. But, tigecycline is not active against Pseudomonas aeruginosa, Proteus mirabilis, and Providencia species.

Tigecycline is extensively distributed into various tissues (Vd: 7-9 L/kg); protein binding: 71-89%; tigecycline is not extensively metabolized; primarily eliminated by biliary and fecal excretion (59%) as unchanged form and metabolites; 33% is eliminated in urine (22% as unchanged drug); in severe hepatic impairment, the clearance of tigecycline is reduced by 55%; Elimination half-life: 42.4hr, prolonged by 43% in severe hepatic impairment; tigecycline is not dialyzable by hemodialysis.

Hypersensitivity to Tigecycline.

D

Excretion in maternal milk unknown/ use caution.

Nausea (29.5%), vomiting (15.8 %), diarrhea (13%)

Adults: initial dose 100 mg, followed by 50 mg IV every 12 hours. Intravenous (IV) infusions should be administered over 30 to 60 minutes.Pediatrics: tigecycline is not recommended in patients under 18 years old.

No dosage adjustment is necessary in patients with renal impairment or in patients undergoing hemodialysis.

Stable in NS or D5W. The reconstituted solution must be immediately transferred and further diluted in 100 ml NS or D5W for IV infusion安定性：室溫：6 hrs (輸注液)；冷藏(2-8℃)：24 hrs (輸注液)